source
- AriBio’s oral Alzheimer’s candidate shows significant benefit in monotherapy subgroup in phase 3 trialAriBio’s AR1001, an oral PDE5 inhibitor originally developed for erectile dysfunction, is being tested as a treatment for early Alzheimer’s disease. In the global phase 3 Polaris-AD trial, the dru…
- Sellas vaccine shows 9-month overall survival gain in phase 3 AML trialSellas Life Sciences reported results of a phase 3 trial of its peptide vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The study met its primary endpoint, showing a me…